Pre-market
Loading markets…

Advertisement

Stocks/NASDAQ/TXG

10X Genomics Inc (TXG : NASDAQ)

Common Stock

$74.04

USD

-1.55 (-2.05%)

Last updated: 2026-10-22

Follow TXG

TXG

10X Genomics Inc

Source:WealthAwesomeWealthAwesome
↑ $1.16 (1.69%)
30 day period
$68.59$83.16$97.74Sep 11Oct 2Oct 22

Performance

1 Day

+5.78%

1 Week

+3.41%

1 Month

-4.44%

YTD

+135.26%

Key Statistics

Market Cap

$9.85B

52W High

$102.81

52W Low

$12.34

P/E Ratio

-

50 Day MA

$71.85

200 Day MA

$38.64

Beta

1.99

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
10/22/2026$73.85$75.59$67.25$69.75$69.754,188,461
10/21/2026$70.92$77.55$70.10$75.59$75.593,119,586
10/20/2026$69.52$73.40$67.53$71.46$71.462,854,184
10/19/2026$71.48$72.48$68.50$69.89$69.892,526,691
10/16/2026$71.91$73.99$67.52$69.86$69.863,385,600
10/15/2026$69.35$73.74$68.57$72.39$72.394,305,245
10/14/2026$69.52$74.33$68.45$73.10$73.104,137,567
10/13/2026$74.50$74.55$71.25$71.79$71.794,038,332
10/12/2026$79.18$80.47$71.61$75.19$75.194,080,287
10/9/2026$78.60$85.12$78.52$80.65$80.653,685,000

Analyst Price Targets

Based on 19 analysts covering TXG · as of Oct 15, 2026

📈

Wall Street analysts forecast TXG stock price to rise 4.0% over the next 12 months.

Consensus

Buy

3.68 / 5.00

Avg. Target

US$77.00

+4.0% Upside

Previously US$75.67 on Oct 14, 2026

Current Price

US$74.04

Last close

Analyst Breakdown (19 analysts)

Strong Buy 6
Buy 1
Hold 12
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on TXG's historical volatility

HistoricalForecast68%95%
US$27.51US$72.51US$117.52US$162.52US$207.53US$252.53TodayJun 17Aug 20Oct 22Dec 4Jan 17Mar 1

30-Day Vol

90.2%

Annualized

90-Day Vol

79.6%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

US$83.39

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$74.03US$54.22 – US$101.07
60 trading daysUS$78.57US$50.59 – US$122.03
90 trading daysUS$83.39US$48.63 – US$142.98

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About 10X Genomics Inc

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Financials

Revenue (TTM)
$616.91M
EBITDA
$-41.20M
Profit Margin
-12.18%
ROE (TTM)
-9.40%
EPS (Diluted)
-0.63
Book Value
6.34

Classification

Sector
Health Care
Industry
Life Sciences Tools & Services
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About TXG.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
POMPOMDOCTOR LIMITED American Depositary Shares$3.01+352.77%
MIMIMint Incorporation Limited Class A Ordinary Shares$1.09+118.80%
SHFSSHF Holdings Inc$0.15+71.52%
LESLQLeslie's, Inc.$0.07+63.06%
XHLDTEN Holdings, Inc. Common Stock$0.91+52.46%
WHLRWheeler Real Estate Investment Trust, Inc.$0.53+47.22%
SPHLSpringview Holdings Ltd Class A Ordinary Shares$3.54+45.68%
SVRNOceanPal Inc.$36.76+41.49%

TXG.US news timeline

3 articles covering TXG.US, most recent first

Latest

Why 10X Genomics Inc stock plummeted yesterday

•Stocks

Advertisement